



Autologous hematopoietic stem cell transplantation (autoHSCT) 
is widely applied for the treatment of patients with lymphoid 
malignancies [1, 2]. Standard indications include multiple myeloma 
(MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma 
(NHL). While in MM autoHSCT is used as consolidation of first line 
treatment, for most of lymphoma subtypes it is considered after 
failure of initial chemotherapy. Currently, autoHSCT procedures are 
almost exclusively performed using peripheral blood as a source of 
stem cells, which requires successful mobilization of hematopoietic 
stem cells [3]. The generally accepted minimal level of CD34+ cells 
required for rapid neutrophil and platelet recovery after autoHSCT 
is 2 × 106 cells/kg. However, some data indicate that higher numbers 
are associated with less need for blood product transfusions and 
administration of antibiotics [4-10]. In the case of tandem autoHSCT 
the minimal level of number of collected CD34+ cells is 4.0 × 106 
CD34+ cells/kg body weight [4-10].
Several study groups attempted to identify factors associated with the 
risk of mobilization failure. The first prognostic system was elaborated 
by Gruppo Italiano Trapianto di Midollo Osseo in 2012 [11]. More 
recently, Olivieri et al [12] built on real large representative data a score 
to “rule in” patients at very high risk for poor mobilizers before starting 
mobilization, allowing changes in clinical management, to avoid highly 
likely mobilization failure. Predicted poor mobilizer score included as 
risk factors: increasing age, diagnosis of NHL, positive bone marrow 
biopsy or cytopenias before mobilization, previous mobilization failure, 
priming strategy with G-CSF alone, or without upfront plerixafor. 
Mobilization regimens may either be “steady state” i.e. using 
granulocyte-colony stimulating factor (G-CSF) alone or may be 
based on G-CSF in combination with chemotherapy, most frequently 
cyclophosphamide at the dose of 1.5-7 g/m2 or lymphoma-specific 
salvage regimens [9, 10]. Unfortunately, 5-30% of patients fail to 
mobilize sufficient numbers of CD34+ cells, thus requiring additional 
attempts [11-13]. New mobilization strategies are being explored 
including the use of plerixafor, a CXCR4 inhibitor, in combination with 
G-CSF, with or without chemotherapy. According to initial studies 
this agent enabled a sufficient CD34+ cell harvest in 64.8-81.6% of 
proven or predicted poor mobilizers [13-17]. Unfortunately, such 
treatment is expensive, and therefore should be utilized in patients 
who are most likely to benefit [18]. Furthermore, attempts to optimize 
the timing and dosage of plerixafor are still needed [19-24].
Plerixafor for patients who fail cytokine- 
or chemotherapy-based stem cell 
mobilization: Results of a prospective 
study by the Polish Lymphoma Research 
Group (PLRG)
Abstract
Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. 
The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell 
mobilization.
This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The 
drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34+ cell output during 
current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 106 CD34+ cells/kg for single autoHSCT 
or ≥ 4 × 106 CD34+ cells/kg for double procedure.
The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected 
CD34+ cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. The number 
of circulating CD34+ cells increased after the use of plerixafor regardless of baseline values. The median fold increase was 3.3 (0.3-155).
Data from this observational study confirm high efficacy of plerixafor used in routine clinical practice as salvage for patients with lymphoid 
malignancies failing conventional stem cell mobilization.
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The goal of this study was to evaluate efficacy of plerixafor used in 
a “real life” setting, i.e. in centers belonging to the Polish Lymphoma 
Research Group (PLRG). Our intention was also to identify potential 




This was a prospective, non-interventional, observational study, 
conducted in 11 PLRG centers, which routinely use G-CSF and 
plerixafor for stem cell mobilization. Data on all consecutive adult 
patients treated with plerixafor were reported to a central database 
and included in the analysis. The enrollment period for this study was 
15 months or up to a minimum 100 patients enrolled. The required set 
of data included: demographics, details on diagnosis and preceding 
chemo- and radiotherapy, details on previous mobilization attempts 
patients as well as details on current mobilization using plerixafor. 
The study was conducted in compliance with the Declaration of 
Helsinki and Good Clinical Practice Guidelines and was approved by 
the Institutional Ethics Committee. All participating patients provided 
written informed consent.
Plerixafor use and leukaphereses
In line with the Polish regulations regarding reimbursement of 
plerixafor by public sources the drug could be used in the following 
cases:
 y unsuccessful previous mobilization defined as collection of 
< 2.0 × 106 CD34+ cells/kg body weight when a single autoHSCT 
was planned or < 4.0 × 106 CD34+ cells/kg body weight when 
a double autoHSCT was intended, 
 y despite the use of an adequate mobilization regimen (G-CSF 10 
μg/ kg, when given as monotherapy or at least 5 μg/kg, when 
given after chemotherapy), maximum stem cell count in the 
peripheral blood was < 10/μL 4-6 days after the onset of G-CSF 
administration as monotherapy or within 20 days after the onset 
of administration of chemotherapy in combination with G-CSF.
For the decision to start leukaphereses the number of circulating 
CD34+ cells was first evaluated on the second day of neutrophil 
recovery > 1 × 109/L in patients who experienced grade 3 or 4 
neutropenia or, in the remaining patients, on the first day with 
increase of neutrophil count. The analysis was done using flow 
cytometry, according to local protocols. Leukaphereses were started 
when the CD34+ blood level was at least 10 cells/μl. If the level was 
not achieved, G-CSF administration was continued or/and plerixafor 
was added, and CD34+ cell counted until CD34+ level decreased 
compared to the preceding day.
Exact duration of G-CSF and/or plerixafor administration could vary 
according to local policies and plerixafor reimbursement schedule. 
Leukaphereses were performed using Spectra-Optia Apheresis 
System (Caridia nBCT, Inc., Lakewood, CO, USA) in three centers 
and using Cobe Spectra (Cobe BCT, Lakewood, CO, USA) in eight 
centers, according to the manufacturer’s protocols for mononuclear 
cell harvesting, processing 2 blood volumes. The target CD34+ cell 
yield was > 2 × 106/kg before single or 4.0 × 106 CD34+ cells/kg body 
weight before the tandem transplantation.
Study endpoints
The percentage of patients with successful mobilization i.e. who 
collected ≥ 2 × 106 CD34+ cells/kg for single autoHSCT or ≥ 4 × 106 
CD34+ cells/kg for double procedure, accordingly, was the primary 
study end-point. The total CD34+ cell yield and the number of 
leukaphereses needed to obtain the transplant material, as well as 
fold increase of CD34+ count in peripheral blood before and after 1st 
plerixafor administration were secondary end-points.
Statistical methods
The statistical analysis included data from all enrolled patients. Chi2 
test analysis was used to evaluate impact of potential prognostic 
factors with the rates of succesful mobilization. Differences with 
p values < 0.05 were considered statistically significant. Statistical 
analysis was performed using Statistica software version 13 (StatSoft 
Inc., Tulsa, OK, USA).
Results
Patient characteristics
Between October 2015 and February 2017, 109 patients were 
enrolled in the study, including 64 (59%) men and 45 (41%) women, 
with median age 55 years (range, 20-71 years). Forty-three patients 
(39%) had MM while remaining individuals were diagnosed with 
either NHL or HL. Most patients had been pre-treated with at least 
2 lines of systemic therapy, including autoHSCT in 25% of cases. In 
67 (61%) patients, plerixafor was used after preceding mobilization 
failure while in remainig ones, because of insufficient CD4+ cell output, 
during current mobilization approach. All 109 patients were classified 
as ‘predicted poor mobilizers’, according to Gruppo Italiano Trapianto 
di Midollo Osseo [11, 12]. Detailed patients characteristics are listed in 
table I. In 91 (83%) cases a single autoHSCT was planned while 18 
(17%) patients were intended for a double procedure.
Mobilization with plerixafor
There were 69/109 (63%) participants who received plerixafor in the 
context of mobilizing or disease-oriented chemotherapy combined 
with G-CSF. The remaining 40 (37%) patients received G-CSF alone 
and plerixafor (Tab. II). Among chemotherapy-based regimens 
intermediate-dose cytarabine with G-CSF was most frequently used, 
following previous PLRG experience [19, 23, 26]. The median number 
of plerixafor doses was 2 (range, 1-4). The median single dose was 
0.25/kg (range, 0.1-0.48).
Efficacy of mobilization using plerixafor
In 38 (35%) patients the required number of CD34+ cells/kg were 
collected with a maximum of two plerixafor administrations while 
the additional 22 patients (20%) requried the subsequent doses. 
The total sucess rate was 55% (55% for patients intended for single 
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and 56% for those planned for tandem autoHSCT). The number 
of leukaphereses and respective rates of patients achieving the 
required CD34+ cell yield is presented in table III. The total number of 
collected cells was 2.4 (0-11.5) CD34+ cells/kg for patients intended 
for a single transplantation while 4 (0.6-16.9) CD34+ cells/kg when 
double procedure was planned.
The number of circulating CD34+ cells increased after the use of 
plerixafor regardless of baseline values (Tab. IV). The median fold 
increase was 3.3 (range, 0.3-155). For patients with baseline number 
of circulationg CD34+ cells < 5/µL, between 5 and < 10/, and 
≥ 10/µL, the rates of successful mobilization were 43%, 80% and 
55% respectively.
Factors affecting efficacy of mobilization with the use 
of plerixafor
A univariate analysis was performed to evaluate associations of 
potential prognostic factors with the rate of successful mobilization. 
The following factors were analyzed: age, performance status, type of 
mobilization, diagnosis, number of preceding lines of chemotherapy, 
preceding radiotherapy, preceding autoHSCT. However, differences 
for none of the variables were statistically significant (data not shown).
Efficacy of mobilization according to physisian’s 
assessment 
Investigators were asked for their subjective opinion regarding the 
efficacy of plerixafor used for stem cell mobilization. Most physicians 
stated that it enabled either a single or tandem transplantation. 
According to 25% of investigators plerixafor shortened the apheresis 
procedure and according to 23% of physicians it allowed diminishing 
intensity of chemotherapy (Tab. V).
Toxicity and supportive care
Twenty-two adverse events (AE) were reported in 12 patients 
according to World Health Organization (WHO) Toxicity Grading 
Scale. There were 7 AEs of grade 3-4, however, none of them was 
assessed to be associated with administration of plerixafor. Ten AEs 
were evaluated as related to plerixafor, most frequently diarrhoea 
(n = 3), abominal pain (n = 2) and muscular pain (n = 2) (Tab. VI).
Discussion
This is the first prospective multicenter observational study to 
summarize experience on stem cells mobilization procedures 
for patients with NHL/HL/MM referred for autoHSCT in Polish 
hematology centers. The aim of this study was to assess successful 
collection rate of hematopoietic stem cell (HSC) mobilization with the 
use of plerixafor in current or proven poor mobilizers, in daily clinical 
practice.
In many studies, clinical benefits of engraftment rate and overall 
survival have been analyzed and point toward a correlation between 
higher CD34+ cell dose and faster engraftment and platelet recovery 
[4, 6, 7]. The search for an optimal mobilization regimen and efficient 
collection even in very poor mobilizers was a subject of series of 
















Bone marrow involvement 81 (74%)
Previous radiotherapy 27 (25%)
Previous bone marrow irradiation 23 (21%)
Previous autoHSCT 19 (17%)
Previous treatment with melphalan 15 (14%)
Previous treatment with lenalidomide 13 (12%)
≥ 2 lines of preceding chemotharapy 80 (73%)
Previous failed stem cell mobilization 67 (61%)
G-CSF alone 18 (17%)
G-CSF + mobilizing CHT 30 (28%)
G-CSF + disease-oriented CHT 17 (16%)
G-CSF + plerixafor 2 (2%)
ECOG – Eastern Cooperative Oncology Group, MM – multiple myeloma; NHL – 
non-Hodgkin lymphoma, HL – Hodgkin lymphoma, autoHSCT – autologous 
hematopoietic stem cell transplantation, G-CSF – granulocyte-colony growth 
factor, CHT – chemotherapy
Table II. Current stem cell mobilization with plerixafor (N = 109)
G-CSF alone 40 (37%)
G-CSF + CHT* 69 (63%)
G-CSF + cytarabine 22 (20%)
G-CSF + cyclophosphamide 14 (13%)
G-CSF + other mobilizing CHT 15 (14%)
G-CSF + disease-oriented CHT 18 (16%)
* CHT: chemotherapy
Table III. Rates of successful CD34+ cell collection according to 
the number of leukaphereses
No of leukaphereses
Patients with successful mobilization 











prospective, randomized clinical trials, reviewed by Sheppard 
et al. [10]. One way to achieve effective mobilization of hematopoietic 
cells is to use G-CSF in combination with chemotherapy instead of 
G-CSF alone. It has been postulated that addition of chemotherapy 
may contribute to in vivo purging thus reducing the risk of graft 
contamination with residual malignant cells. This hypothesis, however, 
has not been confirmed in the clinical setting. Among various 
protocols reported in the literature, DHAP (dexamethasone, cytarbine, 
and cisplatin) with or without rituximab is one of the most widely used 
regimens. It produces a high rate of complete or partial responses in 
patients with relapsed or refractory HL as well as both indolent and 
aggressive NHL [25-27]. In the analysis by the PLRG, intermediate-
dose cytarabine (ID-AraC) + G-CSF was compared to DHAP + 
G-CSF for stem cell mobilization in patients with lymphoma. In the ID-
AraC group, 96% of patients collected at least 2 × 106 CD34+ cells/kg 
compared with 71% in the DHAP group (p = 0.0006) [28]. At 
the time of that study plerixafor was not available in Poland [28]. 
The efficacy of ID-AraC as a first or second mobilization was also 
documented in patients with MM [29, 30]. In the population of poor 
mobilizers and/or after failure of previous mobilization, administration 
of plerixafor has been considered as a good and cost-effective 
alternative to chemotherapy [31, 32]. Addition of plerixafor to G-CSF 
is useful to achieve efficient collection even in very poor mobilizers 
as a hope for patients with diminished hematopoietic function [13-
17, 19]. Cost-effectiveness of hematopoietic stem cell mobilization 
strategies including plerixafor in MM and lymphoma patients have 
been discussed and agreed by many authors [18, 31, 32]. There are 
several studies regarding the additional cost related to the use of 
plerixafor under different protocols. These costs depend on local fees 
and prices as well as the perspective adopted in the cost analysis; 
however, most studies concluded that the use of plerixafor led to an 
additional but acceptable cost, given the clinical benefit obtained 
[31-34]. According to the current practice, the option of in-hospital 
or home administration for plerixafor injection to poor mobilizers has 
Table IV. Effect of the use of plerixafor on the number of circulating CD34+ cells
Baseline number of circulating CD34+ cells/µL
Any < 5 5 < 10 ≥ 10
N 81 43 8 30
























The analysis was restricted to 81 patients with available data.
Table V. Final physician’s assessment of mobilization effect (more than one answer possible)
Plerixafor administration: No of indications
enabled a single transplant 58 (53%)
enabled a tandem transplant 9 (8%)
desired number of CD34+ cells was achieved 12 (11%)
shortened apheresis procedure 27 (25%)
gave a foreseeable effect and made it easy to plan apheresis procedure 11 (10%)
it made diminishing of chemotherapy mobilization possible 25 (23%)
other, including inefficacy 15 (14%)
Table VI. Adverse events
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Any grade Relation to the use of Plerixafor
Headache 1 (1%) – – – 1 (1%) Yes
Diarrhoea 2 (2%) 1 (1%) – – 3 (3%) Possible
Abdominal pain 1 (1%) 1 (1%) – – 2 (2%) Possible
Nausea – 1 (1%) – – 1 (%) Possible
Rash 1 (1%) – – – 1 (%) Yes
Muscular pain 2 (2%) – – – 2 (2%) Yes
Haemorrhage – – 1 (1%) – 1 (1%) No
Cold agglutinin disease – – – 1 (1%) 1 (1%) No
Infection – 1 (1%) – 1 (1%) 2 (2%) No
Tumor lysis syndrome – – – 1 (1%) 1 (1%) No
Polyneuropathy – 1 (1%) 1 (1%) 1 (1%) 3 (3%) No
Body weight loss – – 1 (1%) – 1 (1%) No
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no adverse consequences on subsequent hematopoietic stem cell 
harvest [33].
In our study, despite a heavily pretreated and poorly mobilizing 
patient population, administration of plerixafor allowed the collection 
of a sufficient number for stem cells in 55% of patients referred for 
single autoHSCT and 56% of those planned for double procedure. 
We were unable to distinguish a subgroup of patients who 
may be at risk of failure after plerixafor-based mobilization. The 
effect was comparable regardless of laboratory parameters including 
the number of circulating CD34+ cells prior to drug administration. In 
addition, none of the clinical features was associated with the risk of 
mobilization failure in an univariate analysis. Finally, the therapy was 
well tolerated with no serious adverse events relative to administration 
of plerixafor. These findings should be useful to create a national 
guideline regarding strategies to optimize stem cell mobilization.
Conclusion
Plerixafor treatment is a valuable therapeutic option for NHL, HL, MM 
patients scheduled for autoHSCT with risk factors for mobilization 
failure, with minor toxicity and very good efficacy.
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